The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Krebs Cycle Metabolite Profiling for Identification and Stratification of Pheochromocytomas/Paragangliomas due to Succinate Dehydrogenase Deficiency
Open accessAbstract
Context: Mutations of succinate dehydrogenase A/B/C/D genes (SDHx) increase susceptibility to development of pheochromocytomas and paragangliomas (PPGLs), with particularly high rates of malignancy associated with SDHB mutations. Objective: We assessed whether altered succinate dehydrogenase product-precursor relationships, manifested by differences in tumor ratios of succinate to fumarate or other metabolites, might aid in identifying and stratifying patients with SDHx mutations. Design, Setting, and Patients: PPGL tumor specimens from 233 patients, including 45 with SDHx mutations, were provided from eight tertiary referral centers for mass spectrometric analyses of Krebs cycle metabolites. Main Outcome Measure: Diagnostic performance of the succinate:fumarate ratio for identification of pathogenic SDHx mutations. Results: SDH-deficient PPGLs were characterized by 25-fold higher succinate and 80% lower fumarate, cis-aconitate, and isocitrate tissue levels than PPGLs without SDHx mutations. Receiver-operating characteristic curves for use of ratios of succinate to fumarate or to cis-aconitate and isocitrate to identify SDHx mutations indicated areas under curves of 0.94 to 0.96; an optimal cut-off of 97.7 for the succinate:fumarate ratio provided a diagnostic sensitivity of 93% at a specificity of 97% to identify SDHX-mutated PPGLs. Succinate:fumarate ratios were higher in both SDHB-mutated and metastatic tumors than in those due to SDHD/C mutations or without metastases. Conclusions: Mass spectrometric-based measurements of ratios of succinate:fumarate and other metabolites in PPGLs offer a useful method to identify patients for testing of SDHx mutations, with additional utility to quantitatively assess functionality of mutations and metabolic factors responsible for malignant risk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In 2008, mutation of SDH was discovered in cancers such as paraganglioma and pheochromocytoma cells124. Later, similar observations were made in gastrointestinal tumors, neuroblastomas, renal tumors, thyroid tumors, and testicular tumors125,126.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [124]
Citations
Cites
Succinate is an inflammatory signal that induces IL-1β through HIF-1α
Tannahill, G. M., Curtis, A. M., Adamik, J., Palsson-McDermott, E. M., McGettrick, A. F., Goel, G., Frezza, C., Bernard, N. J., Kelly, B., Foley, N. H., et al. (2013) · Nature · doi:10.1038/nature11986 · Cited by 4,176
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108
Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi227 · Cited by 865
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
Choi, C., Ganji, S. K., DeBerardinis, R. J., Hatanpaa, K. J., Rakheja, D., Kovacs, Z., Yang, X.-L., Mashimo, T., Raisanen, J. M., Marin-Valencia, I., et al. (2012) · Nature Medicine · doi:10.1038/nm.2682 · Cited by 839
SDH mutations establish a hypermethylator phenotype in paraganglioma
Letouzé, E., Martinelli, C., Loriot, C., Burnichon, N., Abermil, N., Ottolenghi, C., Janin, M., Menara, M., Nguyen, A. T., Benit, P., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.04.018 · Cited by 776
Janeway, K. A., Kim, S. Y., Lodish, M., Nosé, V., Rustin, P., Gaal, J., Dahia, P. L. M., Liegl, B., Ball, E. R., Raygada, M., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009199108 · Cited by 628
Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas.
Gimenez‐Roqueplo, A., Favier, J., Rustin, P., Rieubland, C., Crespin, M., Nau, V., Kien, P. K. V., Corvol, P. L., Plouin, P., & Jeunemaı̂tre, X. (2003) · PubMed · Cited by 542
Eisenhofer, G., Lenders, J. W. M., Siegert, G., Bornstein, S. R., Friberg, P., Milosevic, D., Mannelli, M., Linehan, W. M., Adams, K. T., Timmers, H. J. L. M., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.07.016 · Cited by 375
Self-citationGermline SDHB Mutations and Familial Renal Cell Carcinoma
Ricketts, C. J., Woodward, E. R., Killick, P., Morris, M. R., Astuti, D., Latif, F., & Maher, E. R. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn254 · Cited by 354
An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes
Gimenez‐Roqueplo, A., Dahia, P. L. M., & Robledo, M. (2012) · Hormone and Metabolic Research · doi:10.1055/s-0031-1301302 · Cited by 289
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–135 of 135
Erhart, P., Körfer, D., Hoffmann-Wieker, C. M., Gieldon, L., Dikow, N., Wielpütz, M. O., Plinkert, P. K., Κender, Ζ., Szendrödi, J., Schaaf, C. P., et al. (2022) · Gefässchirurgie · doi:10.1007/s00772-022-00919-9 · Cited by 5
Evolving Clinical Presentation and Assessment of Pheochromocytoma: A Review
MERCADO-ASIS, L. B., Siao, R. M., & Amba, N. F. (2017) · Journal of Medicine University of Santo Tomas · doi:10.35460/2546-1621.2017-0050 · Cited by 5
The Role of the Metabolome and Non-Coding RNA on Pheochromocytomas and Paragangliomas: An Update
Bouça, B., Bogalho, P., Rizzo, M., & Silva‐Nunes, J. (2022) · Metabolites · doi:10.3390/metabo12020131 · Cited by 5
Germline SDHB‐inactivating mutation in gastric spindle cell sarcoma
Heilig, C. E., Horak, P., Lipka, D. B., Möck, A., Uhrig, S., Kreutzfeldt, S., Richter, S., Gieldon, L., Fröhlich, M., Hutter, B., et al. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22876 · Cited by 5
Self-citationMiltenburg, J. B., Gorissen, M., van Outersterp, I., Versteeg, I., Nowak, A., Rodenburg, R. J., van Herwaarden, A. E., Olthaar, A. J., Küsters, B., Conrad, C., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137262 · Cited by 4
Self-citationHelm, J., Drukewitz, S., Poser, I., Richter, S., Friedemann, M., William, D., Mohr, H., Nölting, S., Robledo, M., Bornstein, S. R., et al. (2022) · Cells · doi:10.3390/cells11030560 · Cited by 4
Self-citationImplications of SDHB genetic testing in patients with sporadic pheochromocytoma
Maignan, A., Guérin, C., Julliard, V., Paladino, N. C., Kim, E., Roche, P., Castinetti, F., Essamet, W., Mancini, J., Impériale, A., et al. (2017) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-017-1564-y · Cited by 4
Precision Medicine in Adrenal Disorders: the Next Generation
Ghayee, H. K., Vinik, A. I., & Pacák, K. (2017) · Endocrine Practice · doi:10.4158/ep161716.ra · Cited by 4
Zhou, Y., Cui, Y., Li, T., & Tong, A. (2026) · HORMONES · doi:10.1007/s42000-026-00792-1 · Cited by 2
The Role of the Surgical Pathologist in the Recognition of Hereditary SDH-Deficient Tumor Syndromes
Juhlin, C. C., & Mete, Ö. (2026) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000541 · Cited by 2
Amore, F., Garella, R., Santi, A., Guasti, D., Martinelli, S., Canu, L., Bani, D., Neužil, J., Maggi, M., Squecco, R., et al. (2023) · Endocrine Related Cancer · doi:10.1530/erc-23-0167 · Cited by 2
Self-citationGenetic Alterations in Pheochromocytoma and Paraganglioma
Welander, J. (2015) · Linköping University medical dissertations · doi:10.3384/diss.diva-114806 · Cited by 2
Sijko-Szpańska, M., Janasik, B., Wąsowicz, W., & Kozłowska, L. (2023) · Metabolites · doi:10.3390/metabo13010070 · Cited by 1
The 3PAs syndrome and succinate dehydrogenase deficiency in pituitary tumors
Xekouki, P., Daraki, V. N., Betsi, G., Chrysoulaki, M., Sfakiotaki, M., Mytilinaiou, M. G., & Stratakis, C. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814537-1.00001-4 · Cited by 1
Pro-tumoural effects of vitamin C supplementation in a zebrafish model for SDHB -associated PPGL
Miltenburg, J. B., Strijker, N., Gorissen, M., ten Seldam, F., van Woerkom, L., Zethof, J., Küsters, B., Peitzsch, M., Timmers, H. J. L. M., & Dona, M. (2025) · Endocrine Related Cancer · doi:10.1530/erc-25-0370 · Cited by 1
Self-citationZhao, X.-P., Mai, C.-T., Zhao, Y., Zhou, X.-Y., Lai, N.-H., Zhang, X.-J., & Fan, X. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189590 · Cited by 1
Fraissinet, F., Charpentier, T., Girot, H., Brunel, V., Prévost, G., & Lopez, A.-G. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121073 · Cited by 1
Measuring Tumor Succinate and Fumarate to Resolve Pathogenicity of anSDHAVariant
Davidoff, D., Luxford, C., Kim, E., Novos, T., Horvath, A. R., Gill, A. J., Dwight, T., Clifton-Bligh, R. J., & Burgess, J. R. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvab004 · Cited by 1
Metastatic risk factors in pheochromocytoma/paraganglioma
Rebrova, D. V., Логинова, О. И., Vorobyev, S. L., Ворохобина, Н. В., Kozorezova, E. S., Indeikin, F. A., Savelyeva, T. V., Sleptsov, I. V., Chernikov, R. A., Ea, F., et al. (2023) · Problems of Endocrinology · doi:10.14341/probl13331 · Cited by 1
Radionuclide Imaging of Pheochromocytoma and Paraganglioma in the Era of Multi-omics
Timmers, H. J. L. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-46038-3_12 · Cited by 1
Self-citationSuccinate dehydrogenase variants in paraganglioma: why are B subunit variants ‘bad’?
Gruber, L., Hart, S. N., & Maher, L. J., III (2023) · Endocrine Oncology · doi:10.1530/eo-22-0093 · Cited by 1
Role of microenvironment on neuroblastoma SK-N-AS SDHB silenced cell metabolism and function
Rapizzi, E., Fucci, R., Giannoni, E., Canu, L., Richter, S., Cirri, P., & Mannelli, M. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.37.oc8.2 · Cited by 1
Self-citationde Nicolás‐Hernández, J., Arenas, A., Valdivia, C., Santos, M., Lanillos, J., Bechmann, N., Peitzsch, M., Gil, E., Monteagudo, M., Mellid, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.24.632989 · Cited by 1
Self-citationTumor Metabolism and Metabolomics of Pheochromocytomas and Paragangliomas
Richter, S., & Eisenhofer, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-46038-3_11
Self-citationRôle de la succinate déshydrogénase dans le cancer
Moog, S., & Favier, J. (2022) · médecine/sciences · doi:10.1051/medsci/2022024 · Cited by 3
Hereditary Endocrine Tumor Registries
Moore, E. C., Ioannou, L., Ruseckaite, R., Serpell, J. W., & Ahern, S. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac194
Succinate as an Oncometabolite in Endocrine, Mesenchymal, and Epithelial Tumors
Yazdi, S. A. M., & Nazar, E. (2022) · Iranian Red Crescent Medical Journal · doi:10.32592/ircmj.2022.24.12.2395
Goncalves, J., Moog, S., Morin, A., Gentric, G., Müller, S., Morrell, A. P., Kľučková, K., Stewart, T. J., Andoniadou, C. L., Lussey‐Lepoutre, C., et al. (2023) · doi:10.1158/0008-5472.c.6513153.v1
Editorial: A year in review: discussions in adrenal endocrinology
Kraljević, I. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1291582
Masood, A., Malkawi, A. K., Siaj, M., & Rahman, A. M. A. (2023) · Springer eBooks · doi:10.1007/978-981-99-5162-8_9
In vivo and in vitro analysis of functional effects of the SDHD H50R variant
Priya, S., Chakravarthy, K., Ziegler, E., Vesco, X., LaPerle, K., Zhang, X., & Kirschner, L. S. (2025) · Endocrine Related Cancer · doi:10.1530/erc-24-0337
Pheochromocytoma and paraganglioma syndromes in the genomic era
Kuo, M. J. M., & Pacák, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00242-9
Tissot, F. S. (2017) · theses.fr (ABES) · doi:10.70675/15252dfez0dfez4a42z83f4z21be7c773c9d
Impact des mutations SDH sur la réponse antitumorale et identification de nouveaux biomarqueurs
Lamy, C. (2021) · theses.fr (ABES) · doi:10.70675/036f6787z50daz43e6zbeafzbcebfb700048
Cole, Y., Abramovich, I., Fernández-García, J., Docquier, F., MacFarlane, J., Xu, X., Andrésson, Þ., Indig, I. H., Wang, H., Krishnan, A. Y., et al. (2026) · Endocrine Related Cancer · doi:10.1530/erc-26-0323
Metadata
- Authors
- Richter, S., Peitzsch, M., Rapizzi, E., Lenders, J. W., Qin, N., de Cubas, A. A., Schiavi, F., Rao, J. U., Beuschlein, F., Quinkler, M., Timmers, H. J., Opocher, G., Mannelli, M., Pacak, K., Robledo, M., & Eisenhofer, G.
- Affiliations
- University Hospital Carl Gustav Carus (DE)
- University of Florence (IT)
- Radboud University Medical Center (NL)
- Hereditary Endocrine Cancer Group (A.A.C., M.R.), CNIO, Madrid, Spain
- Istituto Oncologico Veneto (IT)
- LMU Klinikum (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K.P.), National Institutes of Health, 10 Center Drive, MSC-1109, Bethesda, Maryland 20892-1109
- Spanish National Cancer Research Centre (ES)
- Corresponding author
- Richter, Susan
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2014-10-01
- Volume
- 99
- Issue
- 10
- Pages
- 3903-3911
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4184070
- OpenAlex
- W2116263600
- Cited by
- 135
- References
- 35
- Citations by year
- 2026: 6 · 2025: 5 · 2024: 6 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 14 · 2019: 11 · 2018: 8 · 2017: 12 · 2016: 10 · 2015: 14 · 2014: 1
- FWCI
- 12.24
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Oncology › Neuroblastoma Research and Treatments
- Keywords
- pheochromocytoma, paraganglioma, succinate dehydrogenase deficiency, SDHx mutations, Krebs cycle metabolites, SDHB mutation, metastasis, mutation detection, isocitrate, cis-aconitate
- MeSH terms
- Adolescent, Adrenal Gland Neoplasms, Adult, Aged, Citric Acid Cycle, Female, Follow-Up Studies, Fumarates, Humans, Male, Metabolic Diseases, Middle Aged, Paraganglioma, Pheochromocytoma, Sensitivity and Specificity, Succinate Dehydrogenase, Germ-Line Mutation, Succinic Acid, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
